Myungmoon Phar (KO:017180) — Market Cap & Net Worth
Market Cap & Net Worth: Myungmoon Phar (017180)
Myungmoon Phar (KO:017180) has a market capitalization of $29.36 Million (₩43.32 Billion) as of September 18, 2026. Listed on the KO stock exchange, this Korea-based company holds position #23948 globally and #1672 in its home market, demonstrating a -2.30% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Myungmoon Phar's stock price ₩1276.00 by its total outstanding shares 33953454 (33.95 Million). Also see balance sheet size of Myungmoon Phar for a full breakdown of the balance sheet.
Myungmoon Phar Market Cap History: 2015 to 2026
Myungmoon Phar's market capitalization history from 2015 to 2026. Data shows change from $56.82 Million to $29.36 Million (-6.18% CAGR). Also see Myungmoon Phar (017180) cash flow conversion for how efficiently the company converts equity into cash flow.
Myungmoon Phar Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Myungmoon Phar's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Myungmoon Phar stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
Myungmoon Phar's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.02x
Myungmoon Phar's market cap is 0.02 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $115.90 Million | $142.18 Billion | $6.75 Billion | 0.00x | 0.02x |
| 2017 | $131.08 Million | $140.14 Billion | $7.81 Billion | 0.00x | 0.02x |
| 2018 | $116.34 Million | $147.50 Billion | $988.27 Million | 0.00x | 0.12x |
| 2019 | $109.28 Million | $149.35 Billion | -$20.40 Billion | 0.00x | N/A |
| 2020 | $167.28 Million | $127.85 Billion | -$27.64 Billion | 0.00x | N/A |
| 2021 | $108.84 Million | $144.76 Billion | -$6.86 Billion | 0.00x | N/A |
| 2022 | $66.04 Million | $152.13 Billion | $7.87 Billion | 0.00x | 0.01x |
| 2023 | $52.58 Million | $169.57 Billion | -$4.52 Billion | 0.00x | N/A |
| 2024 | $41.85 Million | $186.44 Billion | -$3.03 Billion | 0.00x | N/A |
| 2025 | $42.57 Million | $195.25 Billion | $1.90 Billion | 0.00x | 0.02x |
Competitor Companies of 017180 by Market Capitalization
Companies near Myungmoon Phar in the global market cap rankings as of September 18, 2026. Review Myungmoon Phar tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Myungmoon Phar by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #520 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #619 globally with a market cap of $44.48 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #637 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Haleon plc (NYSE:HLN): Ranked #665 globally with a market cap of $41.22 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #520 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #619 | GALDERMA GROUP AG | NYSE:GALDY | $44.48 Billion | $38.15 |
| #637 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.10 |
| #665 | Haleon plc | NYSE:HLN | $41.22 Billion | $9.36 |
Myungmoon Phar Historical Marketcap From 2015 to 2026
Between 2015 and today, Myungmoon Phar's market cap moved from $56.82 Million to $ 29.36 Million, with a yearly change of -6.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩29.36 Million | -31.03% |
| 2025 | ₩42.57 Million | +1.70% |
| 2024 | ₩41.85 Million | -20.39% |
| 2023 | ₩52.58 Million | -20.38% |
| 2022 | ₩66.04 Million | -39.32% |
| 2021 | ₩108.84 Million | -34.94% |
| 2020 | ₩167.28 Million | +53.08% |
| 2019 | ₩109.28 Million | -6.07% |
| 2018 | ₩116.34 Million | -11.25% |
| 2017 | ₩131.08 Million | +13.10% |
| 2016 | ₩115.90 Million | +103.98% |
| 2015 | ₩56.82 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Myungmoon Phar was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $29.36 Million USD |
| MoneyControl | $29.36 Million USD |
| MarketWatch | $29.36 Million USD |
| marketcap.company | $29.36 Million USD |
| Reuters | $29.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Myungmoon Phar
MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hype… Read more